Immunoglobulins in systemic sclerosis management. A large multicenter experience
Autoimmunity Reviews · 2023-11 · 22 (11) · 103441
DOI: 10.1016/j.autrev.2023.103441 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Autoimmunity Reviews, 2023-11. Verfasst von J Tandaipan und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Systemic Autoinmune Diseases, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Myositis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To analyze the effectiveness and safety of intravenous immunoglobulin (IVIG) given in routine care to patients with systemic sclerosis (SSc). METHODS: A retrospective multicenter observational study was conducted in SSc patients treated with IVIG. We collected data on epidemiological parameters and clinical outcomes. Firstly, we assessed changes in organ manifestations during IVIG treatment. Secondly, we analyzed the frequency of adverse effects. The following parameters were collected from baseline to the last follow-up: the patient's weight, modified Rodnan Skin Score (mRSS), modified manual muscle strength scale (MRC), laboratory test(creatine kinase(CK), hemoglobin and protein levels), The University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0 (UCLA GIT 2.0) questionnaire, pulmonary function tests, and echocardiography. RESULTS: Data were collected on 78 patients (82% females; 59% with diffuse SSc). Inflammatory idiopathic myopathy was the most frequent concomitant overlap disease (41%). The time since Raynaud's phenomenon and SSc onset were 8.8 ± 18 and 6.2 ± 6.7 years respectively. The most frequent IVIG indication was myositis (38/78), followed by gastrointestinal (27/78) and cutaneous (17/78) involvement. The median number of cycles given were 5. 54, 53 and 9 patients have been treated previously with glucocorticoids, synthetic disease-modifying antirheumatic drugs and biologic therapies respectively. After IVIG use we found significant improvements in muscular involvement (MRC ≥ 3/5 92% IVIG, p = 0.001 and CK levels from 1149 ± 2026 UI to 217 ± 224 UI, p = 0.02), mRSS (15 ± 12.4 to 13 ± 12.5, p = 0.015) and improvement in total score of UCLA GIT 2.0 (p = 0.05). None Anti-RNA polymerase III patients showed an adequate response in gastrointestinal involvement (0/7) in comparison with other antibodies (0 vs. 25, p = 0,039). Cardiorespiratory involvement remained stable. A total of 12 adverse events were reported with only one withdrawn due to serious adverse effect. CONCLUSIONS: this study suggest that IVIG may improve myositis, gastrointestinal and skin involvement in SSc patients treated in routine care and seems to have a good safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Systemic Autoinmune Diseases, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.
- Unit of Systemic Autoimmune Diseases, Department of Internal Medicine, Hospital Universitari Vall d'Hebrón, Barcelona, Spain.
- Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Department of Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
- Department of Rheumatology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain.
- Department of Internal Medicine, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain.
Zitieren
APA
Tandaipan, J., Guillén-Del-Castillo, A., Simeón-Aznar, C. P., Carreira, P. E., De la Puente, C., Narváez, J., Lluch, J., Rubio-Rivas, M., Alegre-Sancho, J. J., Bonilla, G., Moriano, C., Casafont-Sole, I., García-Vicuña, R., Ortiz-Santamaría, V., Riera, E., Atienza-Mateo, B., Blanco, R., Galisteo, C., Gonzalez-Martin, J. J., …, & Castellví, I. (2023). Immunoglobulins in systemic sclerosis management. A large multicenter experience. Autoimmunity Reviews, 22(11), 103441. https://doi.org/10.1016/j.autrev.2023.103441
Vancouver
Tandaipan J, Guillén-Del-Castillo A, Simeón-Aznar CP, Carreira PE, De la Puente C, Narváez J, et al. Immunoglobulins in systemic sclerosis management. A large multicenter experience. Autoimmunity Reviews. 2023;22(11):103441. doi:10.1016/j.autrev.2023.103441
BibTeX
@article{Tandaipan2023,
author = {Tandaipan, J and Guillén-Del-Castillo, A and Simeón-Aznar, C P and Carreira, P E and De la Puente, C and Narváez, J and Lluch, J and Rubio-Rivas, M and Alegre-Sancho, J J and Bonilla, G and Moriano, C and Casafont-Sole, I and García-Vicuña, R and Ortiz-Santamaría, V and Riera, E and Atienza-Mateo, B and Blanco, R and Galisteo, C and Gonzalez-Martin, J J and Pego-Reigosa, J M and Pros, A and Heredia, S and Castellví, I},
title = {Immunoglobulins in systemic sclerosis management. A large multicenter experience},
journal = {Autoimmunity Reviews},
year = {2023},
volume = {22},
number = {11},
pages = {103441},
doi = {10.1016/j.autrev.2023.103441}
}
EUVIMED